Does the media prefer MDGL or NTRA?

In the previous week, Natera had 23 more articles in the media than Madrigal Pharmaceuticals. MarketBeat recorded 30 mentions for Natera and 7 mentions for Madrigal Pharmaceuticals. Natera's average media sentiment score of 1.34 beat Madrigal Pharmaceuticals' score of 1.08 indicating that Natera is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Madrigal Pharmaceuticals 5 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Natera 25 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to RVMD or MDGL?

In the previous week, Revolution Medicines had 5 more articles in the media than Madrigal Pharmaceuticals. MarketBeat recorded 12 mentions for Revolution Medicines and 7 mentions for Madrigal Pharmaceuticals. Revolution Medicines' average media sentiment score of 1.37 beat Madrigal Pharmaceuticals' score of 1.08 indicating that Revolution Medicines is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Revolution Medicines 10 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive Madrigal Pharmaceuticals 5 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to MDGL or BIIB?

In the previous week, Biogen had 21 more articles in the media than Madrigal Pharmaceuticals. MarketBeat recorded 28 mentions for Biogen and 7 mentions for Madrigal Pharmaceuticals. Biogen's average media sentiment score of 1.35 beat Madrigal Pharmaceuticals' score of 1.08 indicating that Biogen is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Madrigal Pharmaceuticals 5 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Biogen 22 Very Positive mention(s) 3 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor ALNY or MDGL?

In the previous week, Alnylam Pharmaceuticals had 18 more articles in the media than Madrigal Pharmaceuticals. MarketBeat recorded 25 mentions for Alnylam Pharmaceuticals and 7 mentions for Madrigal Pharmaceuticals. Madrigal Pharmaceuticals' average media sentiment score of 1.08 beat Alnylam Pharmaceuticals' score of 0.81 indicating that Madrigal Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Alnylam Pharmaceuticals 11 Very Positive mention(s) 1 Positive mention(s) 10 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Madrigal Pharmaceuticals 5 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Madrigal Pharmaceuticals (MDGL) Competitors

$516.74 -2.35 (-0.45%)

As of 08/21/2026 04:00 PM Eastern

Compare

MDGL vs. NTRA, RVMD, BIIB, ALNY, and INSM

Should you buy Madrigal Pharmaceuticals stock or one of its competitors? Madrigal Pharmaceuticals's main competitors and comparable companies include Natera (NTRA), Revolution Medicines (RVMD), Biogen (BIIB), Alnylam Pharmaceuticals (ALNY), and Insmed (INSM). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Madrigal Pharmaceuticals compare to Natera?

Madrigal Pharmaceuticals (NASDAQ:MDGL) and Natera (NASDAQ:NTRA) are both large-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their valuation, institutional ownership, earnings, media sentiment, risk, profitability, analyst recommendations and dividends.

Natera has a net margin of -7.11% compared to Madrigal Pharmaceuticals' net margin of -25.32%. Natera's return on equity of -11.38% beat Madrigal Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Madrigal Pharmaceuticals	-25.32%	-56.65%	-25.53%
Natera	-7.11%	-11.38%	-7.87%

Natera has higher revenue and earnings than Madrigal Pharmaceuticals. Natera is trading at a lower price-to-earnings ratio than Madrigal Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Madrigal Pharmaceuticals	$958.40M	12.45	-$288.28M	-$12.89	N/A
Natera	$2.31B	20.75	-$208.16M	-$1.36	N/A

98.5% of Madrigal Pharmaceuticals shares are owned by institutional investors. Comparatively, 99.9% of Natera shares are owned by institutional investors. 17.6% of Madrigal Pharmaceuticals shares are owned by insiders. Comparatively, 5.1% of Natera shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Madrigal Pharmaceuticals has a beta of -1.01, meaning that its share price is 201% less volatile than the broader market. Comparatively, Natera has a beta of 1.51, meaning that its share price is 51% more volatile than the broader market.

Madrigal Pharmaceuticals currently has a consensus price target of $689.93, indicating a potential upside of 33.52%. Natera has a consensus price target of $319.38, indicating a potential downside of 3.81%. Given Madrigal Pharmaceuticals' higher probable upside, equities research analysts plainly believe Madrigal Pharmaceuticals is more favorable than Natera.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Madrigal Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	15 Buy rating(s)	0 Strong Buy rating(s)	2.78
Natera	1 Sell rating(s)	4 Hold rating(s)	15 Buy rating(s)	2 Strong Buy rating(s)	2.82

In the previous week, Natera had 23 more articles in the media than Madrigal Pharmaceuticals. MarketBeat recorded 30 mentions for Natera and 7 mentions for Madrigal Pharmaceuticals. Natera's average media sentiment score of 1.34 beat Madrigal Pharmaceuticals' score of 1.08 indicating that Natera is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Madrigal Pharmaceuticals	5 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Natera	25 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Natera beats Madrigal Pharmaceuticals on 13 of the 16 factors compared between the two stocks.

How does Madrigal Pharmaceuticals compare to Revolution Medicines?

Revolution Medicines (NASDAQ:RVMD) and Madrigal Pharmaceuticals (NASDAQ:MDGL) are both large-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their risk, profitability, earnings, dividends, institutional ownership, media sentiment, analyst recommendations and valuation.

Revolution Medicines has a beta of 1.39, suggesting that its stock price is 39% more volatile than the broader market. Comparatively, Madrigal Pharmaceuticals has a beta of -1.01, suggesting that its stock price is 201% less volatile than the broader market.

Madrigal Pharmaceuticals has higher revenue and earnings than Revolution Medicines. Madrigal Pharmaceuticals is trading at a lower price-to-earnings ratio than Revolution Medicines, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Revolution Medicines	$11.58M	3,877.00	-$1.13B	-$8.82	N/A
Madrigal Pharmaceuticals	$958.40M	12.45	-$288.28M	-$12.89	N/A

In the previous week, Revolution Medicines had 5 more articles in the media than Madrigal Pharmaceuticals. MarketBeat recorded 12 mentions for Revolution Medicines and 7 mentions for Madrigal Pharmaceuticals. Revolution Medicines' average media sentiment score of 1.37 beat Madrigal Pharmaceuticals' score of 1.08 indicating that Revolution Medicines is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Revolution Medicines	10 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive
Madrigal Pharmaceuticals	5 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

94.3% of Revolution Medicines shares are owned by institutional investors. Comparatively, 98.5% of Madrigal Pharmaceuticals shares are owned by institutional investors. 7.6% of Revolution Medicines shares are owned by insiders. Comparatively, 17.6% of Madrigal Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Revolution Medicines has a net margin of 0.00% compared to Madrigal Pharmaceuticals' net margin of -25.32%. Madrigal Pharmaceuticals' return on equity of -56.65% beat Revolution Medicines' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Revolution Medicines	N/A	-88.20%	-57.85%
Madrigal Pharmaceuticals	-25.32%	-56.65%	-25.53%

Revolution Medicines currently has a consensus target price of $167.89, indicating a potential downside of 19.85%. Madrigal Pharmaceuticals has a consensus target price of $689.93, indicating a potential upside of 33.52%. Given Madrigal Pharmaceuticals' higher probable upside, analysts clearly believe Madrigal Pharmaceuticals is more favorable than Revolution Medicines.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Revolution Medicines	1 Sell rating(s)	1 Hold rating(s)	18 Buy rating(s)	1 Strong Buy rating(s)	2.90
Madrigal Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	15 Buy rating(s)	0 Strong Buy rating(s)	2.78

Summary

Revolution Medicines beats Madrigal Pharmaceuticals on 10 of the 17 factors compared between the two stocks.

How does Madrigal Pharmaceuticals compare to Biogen?

Madrigal Pharmaceuticals (NASDAQ:MDGL) and Biogen (NASDAQ:BIIB) are both large-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their dividends, valuation, profitability, earnings, institutional ownership, analyst recommendations, risk and media sentiment.

In the previous week, Biogen had 21 more articles in the media than Madrigal Pharmaceuticals. MarketBeat recorded 28 mentions for Biogen and 7 mentions for Madrigal Pharmaceuticals. Biogen's average media sentiment score of 1.35 beat Madrigal Pharmaceuticals' score of 1.08 indicating that Biogen is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Madrigal Pharmaceuticals	5 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Biogen	22 Very Positive mention(s)	3 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

98.5% of Madrigal Pharmaceuticals shares are owned by institutional investors. Comparatively, 87.9% of Biogen shares are owned by institutional investors. 17.6% of Madrigal Pharmaceuticals shares are owned by company insiders. Comparatively, 0.3% of Biogen shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Madrigal Pharmaceuticals has a beta of -1.01, suggesting that its share price is 201% less volatile than the broader market. Comparatively, Biogen has a beta of 0.17, suggesting that its share price is 83% less volatile than the broader market.

Madrigal Pharmaceuticals presently has a consensus price target of $689.93, indicating a potential upside of 33.52%. Biogen has a consensus price target of $227.07, indicating a potential upside of 4.75%. Given Madrigal Pharmaceuticals' stronger consensus rating and higher possible upside, equities analysts plainly believe Madrigal Pharmaceuticals is more favorable than Biogen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Madrigal Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	15 Buy rating(s)	0 Strong Buy rating(s)	2.78
Biogen	1 Sell rating(s)	13 Hold rating(s)	18 Buy rating(s)	1 Strong Buy rating(s)	2.58

Biogen has a net margin of 8.32% compared to Madrigal Pharmaceuticals' net margin of -25.32%. Biogen's return on equity of 11.18% beat Madrigal Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Madrigal Pharmaceuticals	-25.32%	-56.65%	-25.53%
Biogen	8.32%	11.18%	6.88%

Biogen has higher revenue and earnings than Madrigal Pharmaceuticals. Madrigal Pharmaceuticals is trading at a lower price-to-earnings ratio than Biogen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Madrigal Pharmaceuticals	$958.40M	12.45	-$288.28M	-$12.89	N/A
Biogen	$10.03B	3.19	$1.29B	$5.65	38.37

Summary

Biogen beats Madrigal Pharmaceuticals on 12 of the 17 factors compared between the two stocks.

How does Madrigal Pharmaceuticals compare to Alnylam Pharmaceuticals?

Alnylam Pharmaceuticals (NASDAQ:ALNY) and Madrigal Pharmaceuticals (NASDAQ:MDGL) are both large-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their media sentiment, risk, institutional ownership, valuation, profitability, earnings, analyst recommendations and dividends.

Alnylam Pharmaceuticals presently has a consensus target price of $386.62, suggesting a potential upside of 63.67%. Madrigal Pharmaceuticals has a consensus target price of $689.93, suggesting a potential upside of 33.52%. Given Alnylam Pharmaceuticals' stronger consensus rating and higher possible upside, equities research analysts plainly believe Alnylam Pharmaceuticals is more favorable than Madrigal Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alnylam Pharmaceuticals	0 Sell rating(s)	5 Hold rating(s)	15 Buy rating(s)	4 Strong Buy rating(s)	2.96
Madrigal Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	15 Buy rating(s)	0 Strong Buy rating(s)	2.78

In the previous week, Alnylam Pharmaceuticals had 18 more articles in the media than Madrigal Pharmaceuticals. MarketBeat recorded 25 mentions for Alnylam Pharmaceuticals and 7 mentions for Madrigal Pharmaceuticals. Madrigal Pharmaceuticals' average media sentiment score of 1.08 beat Alnylam Pharmaceuticals' score of 0.81 indicating that Madrigal Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Alnylam Pharmaceuticals	11 Very Positive mention(s)	1 Positive mention(s)	10 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Madrigal Pharmaceuticals	5 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Alnylam Pharmaceuticals has higher revenue and earnings than Madrigal Pharmaceuticals. Madrigal Pharmaceuticals is trading at a lower price-to-earnings ratio than Alnylam Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alnylam Pharmaceuticals	$4.80B	6.58	$313.75M	$5.38	43.91
Madrigal Pharmaceuticals	$958.40M	12.45	-$288.28M	-$12.89	N/A

Alnylam Pharmaceuticals has a beta of 0.3, indicating that its share price is 70% less volatile than the broader market. Comparatively, Madrigal Pharmaceuticals has a beta of -1.01, indicating that its share price is 201% less volatile than the broader market.

Alnylam Pharmaceuticals has a net margin of 15.26% compared to Madrigal Pharmaceuticals' net margin of -25.32%. Alnylam Pharmaceuticals' return on equity of 84.93% beat Madrigal Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Alnylam Pharmaceuticals	15.26%	84.93%	14.30%
Madrigal Pharmaceuticals	-25.32%	-56.65%	-25.53%

93.0% of Alnylam Pharmaceuticals shares are owned by institutional investors. Comparatively, 98.5% of Madrigal Pharmaceuticals shares are owned by institutional investors. 0.9% of Alnylam Pharmaceuticals shares are owned by insiders. Comparatively, 17.6% of Madrigal Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Summary

Alnylam Pharmaceuticals beats Madrigal Pharmaceuticals on 12 of the 16 factors compared between the two stocks.

How does Madrigal Pharmaceuticals compare to Insmed?

Madrigal Pharmaceuticals (NASDAQ:MDGL) and Insmed (NASDAQ:INSM) are both large-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their profitability, dividends, institutional ownership, risk, valuation, media sentiment, earnings and analyst recommendations.

Madrigal Pharmaceuticals has higher revenue and earnings than Insmed. Madrigal Pharmaceuticals is trading at a lower price-to-earnings ratio than Insmed, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Madrigal Pharmaceuticals	$958.40M	12.45	-$288.28M	-$12.89	N/A
Insmed	$606.42M	45.29	-$1.28B	-$4.11	N/A

Madrigal Pharmaceuticals presently has a consensus price target of $689.93, suggesting a potential upside of 33.52%. Insmed has a consensus price target of $205.52, suggesting a potential upside of 63.41%. Given Insmed's stronger consensus rating and higher probable upside, analysts clearly believe Insmed is more favorable than Madrigal Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Madrigal Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	15 Buy rating(s)	0 Strong Buy rating(s)	2.78
Insmed	1 Sell rating(s)	0 Hold rating(s)	22 Buy rating(s)	2 Strong Buy rating(s)	3.00

Madrigal Pharmaceuticals has a net margin of -25.32% compared to Insmed's net margin of -76.94%. Madrigal Pharmaceuticals' return on equity of -56.65% beat Insmed's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Madrigal Pharmaceuticals	-25.32%	-56.65%	-25.53%
Insmed	-76.94%	-123.94%	-44.30%

98.5% of Madrigal Pharmaceuticals shares are held by institutional investors. 17.6% of Madrigal Pharmaceuticals shares are held by company insiders. Comparatively, 2.1% of Insmed shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Madrigal Pharmaceuticals has a beta of -1.01, meaning that its share price is 201% less volatile than the broader market. Comparatively, Insmed has a beta of 0.81, meaning that its share price is 19% less volatile than the broader market.

In the previous week, Madrigal Pharmaceuticals had 7 more articles in the media than Insmed. MarketBeat recorded 7 mentions for Madrigal Pharmaceuticals and 0 mentions for Insmed. Insmed's average media sentiment score of 1.84 beat Madrigal Pharmaceuticals' score of 1.08 indicating that Insmed is being referred to more favorably in the news media.

Company	Overall Sentiment
Madrigal Pharmaceuticals	Positive
Insmed	Very Positive

Summary

Insmed beats Madrigal Pharmaceuticals on 9 of the 17 factors compared between the two stocks.

Get Madrigal Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding MDGL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

MDGL vs. The Competition

Export

Metric	Madrigal Pharmaceuticals	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$11.94B	$4.01B	$7.37B	$12.85B
Dividend Yield	N/A	3.64%	2.53%	11.08%
P/E Ratio	-40.09	11.62	272.60	24.24
Price / Sales	12.45	1,338.17	618.96	99.78
Price / Cash	N/A	105.14	78.62	53.99
Price / Book	22.79	16.80	13.05	6.20
Net Income	-$288.28M	-$12.50M	$3.47B	$348.59M
7 Day Performance	1.81%	3.29%	2.09%	0.08%
1 Month Performance	-4.90%	8.23%	6.64%	3.88%
1 Year Performance	24.61%	55.05%	25.02%	16.98%

Madrigal Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
MDGL Madrigal Pharmaceuticals	3.8051 of 5 stars	$516.74 -0.5%	$689.93 +33.5%	+24.6%	$11.94B	$958.40M	N/A	90	Positive News Insider Trade
NTRA Natera	2.5905 of 5 stars	$314.18 +1.4%	$319.38 +1.7%	+100.5%	$44.67B	$2.31B	N/A	6,140	News Coverage Positive News
RVMD Revolution Medicines	2.5369 of 5 stars	$212.00 +4.1%	$166.33 -21.5%	+466.0%	$43.66B	$11.58M	N/A	250	Positive News Analyst Forecast
BIIB Biogen	3.9629 of 5 stars	$209.15 -0.3%	$227.07 +8.6%	+55.6%	$31.00B	$9.89B	37.02	7,500	News Coverage Positive News
ALNY Alnylam Pharmaceuticals	4.9363 of 5 stars	$224.60 -1.8%	$393.86 +75.4%	-48.0%	$30.60B	$3.71B	41.75	2,770	News Coverage Analyst Upgrade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:MDGL) was last updated on 8/23/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Madrigal Pharmaceuticals (MDGL) Competitors

MDGL vs. NTRA, RVMD, BIIB, ALNY, and INSM

How does Madrigal Pharmaceuticals compare to Natera?

Summary

How does Madrigal Pharmaceuticals compare to Revolution Medicines?

Summary

How does Madrigal Pharmaceuticals compare to Biogen?

Summary

How does Madrigal Pharmaceuticals compare to Alnylam Pharmaceuticals?

Summary

How does Madrigal Pharmaceuticals compare to Insmed?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MDGL vs. The Competition

Madrigal Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Madrigal Pharmaceuticals (MDGL) Competitors

MDGL vs. NTRA, RVMD, BIIB, ALNY, and INSM

How does Madrigal Pharmaceuticals compare to Natera?

Is MDGL or NTRA more profitable?

Which has higher earnings and valuation, MDGL or NTRA?

Do insiders & institutionals have more ownership in MDGL or NTRA?

Which has more risk & volatility, MDGL or NTRA?

Do analysts rate MDGL or NTRA?

Does the media prefer MDGL or NTRA?

Summary

How does Madrigal Pharmaceuticals compare to Revolution Medicines?

Which has more risk and volatility, RVMD or MDGL?

Which has higher valuation and earnings, RVMD or MDGL?

Does the media refer more to RVMD or MDGL?

Do institutionals and insiders believe in RVMD or MDGL?

Is RVMD or MDGL more profitable?

Do analysts rate RVMD or MDGL?

Summary

How does Madrigal Pharmaceuticals compare to Biogen?

Does the media refer more to MDGL or BIIB?

Do institutionals & insiders believe in MDGL or BIIB?

Which has more risk & volatility, MDGL or BIIB?

Do analysts rate MDGL or BIIB?

Is MDGL or BIIB more profitable?

Which has preferable earnings & valuation, MDGL or BIIB?

Summary

How does Madrigal Pharmaceuticals compare to Alnylam Pharmaceuticals?

Do analysts rate ALNY or MDGL?

Does the media favor ALNY or MDGL?

Which has stronger earnings & valuation, ALNY or MDGL?

Which has more volatility and risk, ALNY or MDGL?

Is ALNY or MDGL more profitable?

Do institutionals & insiders have more ownership in ALNY or MDGL?

Summary

How does Madrigal Pharmaceuticals compare to Insmed?

Which has higher earnings & valuation, MDGL or INSM?

Do analysts prefer MDGL or INSM?

Is MDGL or INSM more profitable?

Do institutionals and insiders have more ownership in MDGL or INSM?

Which has more volatility and risk, MDGL or INSM?

Does the media refer more to MDGL or INSM?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MDGL vs. The Competition

Madrigal Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools